Advertisement

Management of Episodic Migraine in Children and Adolescents: a Practical Approach

  • Reena Gogia Rastogi
  • Clarimar Borrero-Mejias
  • Carolyn Hickman
  • Kara Stuart Lewis
  • Robert Little
Headache (R B Halker Singh, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Headache

Abstract

Purpose of Review

Episodic migraine is very common in children and adolescents, seen by primary care and specialists. In kids, this can greatly affect quality of life, including significant disability, specifically in terms of missed school and other activities. The goal of this paper is to give an overview of the most up-to-date thoughts on episodic migraine in the pediatric population.

Recent Findings

Current options for both abortive and preventative treatments in kids, as well as specific non-pharmacological and lifestyle management recommendations for children, will be reviewed, as well as options for status migrainosus in the pediatric patient.

Summary

Migraine pathophysiology is similar in adults and children with episodic migraine, but the approach to the management needs to be modified and adjusted in kids. Recognizing the impact on quality of life especially with regard to school and knowing appropriate treatment options can improve treatment and decrease the disability from this disorder.

Keywords

Migraine Pediatric migraine Pediatric episodic migraine Lifestyle management in pediatric migraine Triptans Non-pharmacological treatment modalities in pediatric migraine 

Notes

Compliance with Ethical Standards

Conflict of Interest

Reena Gogia Rastogi is a sub-investigator for Avanir. Clarimar Borrero-Mejias, Carolyn Hickman, Kara Stuart Lewis, and Robert Little each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lewis DW, Diamond S, Scott D, Jones V. Prophylactic treatment of pediatric migraine. Headache. 2004;44:230–7.  https://doi.org/10.1111/j.1526-4610.2004.04052.CrossRefPubMedGoogle Scholar
  2. 2.
    Hamalainen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology. 1997;48(1):103–7.CrossRefGoogle Scholar
  3. 3.
    Khrizman M, Pakalnis A. Management of pediatric migraine: current therapies. Pediatr Ann. 2018;47(2):e55–60.CrossRefGoogle Scholar
  4. 4.
    Richer L, Billinghurst L, Lindsell MA, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016;4:CD005220.PubMedGoogle Scholar
  5. 5.
    Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.CrossRefGoogle Scholar
  6. 6.
    Orr SL, Aubé M, Becker WJ, Davenport WJ, Dilli E, Dodick D, et al. Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia. 2015;35(3):271–84.CrossRefGoogle Scholar
  7. 7.
    James JE. Acute and chronic effects of caffeine on performance, mood, headache, and sleep. Neuropsychobiology. 1998;38:32–41.CrossRefGoogle Scholar
  8. 8.
    Mannix LK, Frame JR, Solomon GD. Alcohol, smoking, and caffeine use among headache patients. Headache. 1997;37:572–6.CrossRefGoogle Scholar
  9. 9.
    Géraud G, Lantéri-Minet M, Lucas C, Valade D, French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther. 2004;26(8):1305–18.CrossRefGoogle Scholar
  10. 10.
    Cianchetti C, Serci MC, Pisano T, Ledda MG. Compression of superficial temporal arteries by a handmade device: a simple way to block or attenuate migraine attacks in children and adolescents. J Child Neurol. 2010;25(1):67–70.CrossRefGoogle Scholar
  11. 11.
    • Szperka CL, Gelfand AA, Hershey AD. Patterns of use of peripheral nerve blocks and trigger point injections for pediatric headache: results of a survey of the American Headache Society Pediatric and Adolescent Section. Headache. 2016;56(10):1597–607. This paper queried pediatric headache providers from the Pediatric and Adolescent Section of the American Headache Society as to the use of nerve blocks in their clinical practice, and was unique in capturing data from this small group. CrossRefGoogle Scholar
  12. 12.
    • Kaye R, et al. SPG blockade reported as a safe and effective migraine headache treatment for children. Presented at the Society of Interventional Radiology Annual Scientific Meeting in March 2017. Appl Radiol. 2017. This paper is unique in presenting extensive clinical cases of SPG blocks used in children for acute migraine treatment. Google Scholar
  13. 13.
    Patterson-Gentile C, Szperka CL. The changing landscape of pediatric migraine therapy: a review. JAMA Neurol. 2018.  https://doi.org/10.1001/jamaneurol.2018.0046.CrossRefGoogle Scholar
  14. 14.
    Sun-Edelstein C, Mauskop A. Foods and supplements in the management of migraine headaches. Clin J Pain. 2009;25(5):446–52.CrossRefGoogle Scholar
  15. 15.
    VanderPluym J. 2018. Retrieved from https://americanmigrainefoundation.org/understanding-migraine/migraine-stroke-heart-disease/Strategies to Avoid Emergency Department Visits for Migraine on May 21, 2018.
  16. 16.
    Fernandez-de-Las-Penas C, Hernandez-Barera V, Carrasco-Garrido V, Alonso-Blanco C, Palacious-Cena D, Jimenez-Sanchez S, et al. Population-based study of migraine in Spanish adults: relation to socio-demographic factors, lifestyle and comorbidity with other conditions. Headache. 2010;11(2):1–13.Google Scholar
  17. 17.
    •• Paruthi S, Brooks LJ, D’Ambrosio C, Hall WA, Kotagal S, Lloyd RM, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. J Clin Sleep Med. 2016;12(6):785–6 An excellent consensus statement on the amount of sleep needed for children and adolescents to promote optimal health.CrossRefGoogle Scholar
  18. 18.
    Varkey E, Hagen K, Zwart J-A. Physical activity and headaches: results from the Nord-Trondelag Health study (HUNT). Cephalalgia. 2008;28(12):1292–7.CrossRefGoogle Scholar
  19. 19.
    Narin S, Pinar L, Erbas D. The effects of exercise and exercise-related changes in blood nitric oxide levels on migraine headache. Clin Rehabil. 2003;17(6):624–30.CrossRefGoogle Scholar
  20. 20.
    Millichap JG, Yee MM. The diet factor in pediatric and adolescent migraine. Neurology. 2003;28(1):9–15.Google Scholar
  21. 21.
    Spigt M, Kuijper E, Schayck C, Troost J, Knipschild P, Linssen V, et al. Increasing the daily water intake for the prophylactic treatment of headache: a pilot trial. Eur J Neurol. 2005;12(9):715–8.CrossRefGoogle Scholar
  22. 22.
    Hickman C, Jacobson D, Melnyk B. Randomized controlled trial of the acceptability, feasibility, and preliminary effects of a cognitive behavioral skills building intervention in adolescents with chronic daily headaches: a pilot study. J Pediatr Health Care. 2015;28(1):5–16.CrossRefGoogle Scholar
  23. 23.
    Nestoriuc Y, Martin A. Efficacy of biofeedback for migraines: a meta-analyses. Pain. 2007;128:111–27.CrossRefGoogle Scholar
  24. 24.
    Nestoriuc Y, Martin A, Andrasik F. Biofeedback treatment for headache disorders: a comprehensive efficacy review. Appl Psychophysiol Biofeedback. 2008;33:125–40.CrossRefGoogle Scholar
  25. 25.
    Kropp P, Meyer B, Landgraf M, Ruscheweyh R, Ebinger F, Straube A. Headache in children: update on biobehavioral treatments. Neuropediatrics. 2013;44:20–4.CrossRefGoogle Scholar
  26. 26.
    Damen L, Bruijn J, Koes BW, Berger MY, Passchier J, Verhagen AP. Prophylactic treatment of migraine in children. Cephalalgia. 2006;26(4):373–83.CrossRefGoogle Scholar
  27. 27.
    Campbell JK, Penzien DB, Wall EM. Evidence-based guidelines for migraine headache: behavioral and physical treatments. US Headache Consortium 2000. Available at https://search.pedio.org.au/search-results/record-detail/9764. Accessed March 7, 2018.
  28. 28.
    Heath R, Saliba M, Mahmasssani O, Major S, Khoury BA. Locus of control moderates the relationship between headache pain and depression. J Headache Face Pain. 2008;9:301–8.CrossRefGoogle Scholar
  29. 29.
    Powers SW, Kashikar-Zuck SM, Allen JR, LeCates SL, Slater SK, Zafar M, et al. Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. J Am Med Assoc. 2013;310(24):2622–30.CrossRefGoogle Scholar
  30. 30.
    Sun-Edelstein C, Mauskop A. Alternative headache treatments: nutraceuticals, behavioral, and physical treatments. Headache. 2011;51(3):469–83.CrossRefGoogle Scholar
  31. 31.
    Diamond S, Diamond-Falk J, DeVeno T. Biofeedback in the treatment of vascular headache. Biofeedback Self Regul. 1978;3(4):385–04.CrossRefGoogle Scholar
  32. 32.
    Kacperski J, Hershey AD. Preventive drugs in childhood and adolescent migraine. Curr Pain Headache Rep. 2014;18:422.  https://doi.org/10.1007/s11916-014-0422-7.CrossRefPubMedGoogle Scholar
  33. 33.
    Hickman C, Lewis KS, Little R, Rastogi RG, Yonker M. Prevention for pediatric and adolescent migraine. Headache. 2015;55:1371–81.  https://doi.org/10.1111/head.12699.CrossRefPubMedGoogle Scholar
  34. 34.
    Hershey AD, Powers SW, Bentti A, DeGrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000;40:539–49.  https://doi.org/10.1046/j.1526-4610.2000.00085.CrossRefPubMedGoogle Scholar
  35. 35.
    Lewis DW, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004;63(12):2215–24.CrossRefGoogle Scholar
  36. 36.
    Winner P, Pearlman EM, Linder SL, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:1304–12.  https://doi.org/10.1111/j.1526-4610.2005.00262.CrossRefPubMedGoogle Scholar
  37. 37.
    Lewis D, Winner P, Saper J, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009;123:924–34.  https://doi.org/10.1542/peds.2008-0642.CrossRefPubMedGoogle Scholar
  38. 38.
    Lakshmi CVS, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol. 2007;(7):829–35.  https://doi.org/10.1177/0883073807304201.CrossRefGoogle Scholar
  39. 39.
    •• Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. NEJM. 2016.  https://doi.org/10.1056/NEJMoa1610384. This article presented the unexpected results of a very robust study of prophylactic medications in pediatric migraine and showed the power of the placebo response in pediatric studies. CrossRefGoogle Scholar
  40. 40.
    • Kacperski J, Bazarsky A. New developments in the prophylactic drug treatment of pediatric migraine: what is new in 2017 and where does it leave us? Curr Pain Headache Rep. 2017;21:38.  https://doi.org/10.1007/s11916-017-0638-4. This article delves deeper into the results and implications of the Childhood and Adolescent Migraine Prevention Study (CHAMP) and discusses how this will affect future studies in pediatric headache. CrossRefPubMedGoogle Scholar
  41. 41.
    Pakalnis A, Kring D. Zonisamide prophylaxis in refractory pediatric headache. Headache. 2006;46:804–7.  https://doi.org/10.1111/j.1526-4610.2006.00455.CrossRefPubMedGoogle Scholar
  42. 42.
    Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache. 2000;40:672–6.  https://doi.org/10.1046/j.1526-4610.2000.040008672.CrossRefPubMedGoogle Scholar
  43. 43.
    Apostol G, Cady RK, Laforet GA, et al. Divalproex extended-release in adolescent migraine prophylaxis: results of a randomized, double-blind, placebo-controlled study. Headache. 2008;48:1012–25.  https://doi.org/10.1111/j.1526-4610.2008.01081.CrossRefPubMedGoogle Scholar
  44. 44.
    Apostol G, Lewis DW, Laforet GA, et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache. 2009;49:45–53.  https://doi.org/10.1111/j.1526-4610.2008.01279.CrossRefPubMedGoogle Scholar
  45. 45.
    Rajdev SK, Wassmer E, Agrawal S, Smith M, Philip SG, Gupta R. Efficacy and tolerability of the use gabapentin for migraine prophylaxis in children. Arch Dis Child. 2012;1997.  https://doi.org/10.1136/archdischild-2012-301885.336.CrossRefGoogle Scholar
  46. 46.
    Mathew NT, Rapoport A, Saper J, Magnus L, Klapper J, Ramadan N, et al. Efficacy of gabapentin in migraine prophylaxis. Headache. 2001;41:119–28.  https://doi.org/10.1046/j.1526-4610.2001.111006119.CrossRefPubMedGoogle Scholar
  47. 47.
    Ashrafi MR, Shabanian R, Zamani GR, Mahfelati F. Sodium valproate versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr Neurol. 2005;9:333–8.  https://doi.org/10.1016/j.ejpn.2005.05.004.CrossRefPubMedGoogle Scholar
  48. 48.
    Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010;12:269–75.  https://doi.org/10.2165/11316270-000000000-00000.CrossRefPubMedGoogle Scholar
  49. 49.
    Eidlitz-Markus T, Dlugatch Y, Haimi-Cohen Y, Goldberg-Stern H, Zeharia A. Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline. Pediatr Neurol. 2012;46(6):345–9.  https://doi.org/10.1016/j.pediatrneurol.2012.03.017.CrossRefPubMedGoogle Scholar
  50. 50.
    Fallah R, Divanizadeh MS, Karimi M, Mirouliaei M, Shamszadeh A. Topiramate and propranolol for prophylaxis of migraine. Indian J Pediatr. 2013;80(11):920–4.  https://doi.org/10.1007/s12098-013-0976-0.CrossRefPubMedGoogle Scholar
  51. 51.
    Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45.CrossRefGoogle Scholar
  52. 52.
    Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21(3):173–5.CrossRefGoogle Scholar
  53. 53.
    Brousseau DC, Duffy SJ, Anderson AC, et al. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43:256–62.CrossRefGoogle Scholar
  54. 54.
    Tanen DA, Miller S, French T, et al. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41(6):847–53.CrossRefGoogle Scholar
  55. 55.
    Trottier ED, Bailey B, Dauphin-Pierre S, et al. Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department. J Emerg Med. 2010;39(2):166–73.CrossRefGoogle Scholar
  56. 56.
    Kabbouche MA, Vockell A-LB, LeCates SL, et al. Tolerability and effectiveness of prochlorperazine for intractable migraine in children. Pediatrics. 2001;107:e62.CrossRefGoogle Scholar
  57. 57.
    Sheridan D, Sun B, O’Brien P, et al. Intravenous sodium valproate for acute pediatric headache. J Emerg Med. 2015;49(4):541–5.CrossRefGoogle Scholar
  58. 58.
    Reiter PD, Nickisch J, Merritt G. Efficacy and tolerability of intravenous valproic acid in acute adolescent migraine. Headache. 2005;45:899–903.CrossRefGoogle Scholar
  59. 59.
    Gertsch E, Loharuka S, Wolter-Warmerdam K, et al. Intravenous magnesium as acute treatment for headaches: a pediatric case series. J Emerg Med. 2014;46:308–12.CrossRefGoogle Scholar
  60. 60.
    Colman I, Friedman BW, Brown MD, et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ. 2008;336(7657):1359–61.CrossRefGoogle Scholar
  61. 61.
    Cobb-Pitstick KM, Hershey AD, O’Brien HL, et al. Factors influencing migraine recurrence after infusion and inpatient migraine treatment in children and adolescents. Headache. 2015;55(10):1397–403.CrossRefGoogle Scholar
  62. 62.
    Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006;46(Suppl 4):S171–81.CrossRefGoogle Scholar
  63. 63.
    Kabbouche MA, Powers SW, Segers A, et al. Inpatient treatment of status migraine with dihydroergotamine in children and adolescents. Headache. 2009;49(1):106–9.CrossRefGoogle Scholar
  64. 64.
    Loder E, Weizenbaum E, Frishberg B, et al. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache. 2013;53:1651–9.CrossRefGoogle Scholar
  65. 65.
    Richer LP, Laycock K, Millar K, et al. Treatment of children with migraine in emergency departments: national practice variation study. Pediatrics. 2010;126(1):e150–5.CrossRefGoogle Scholar
  66. 66.
    • Sheridan DC, Meckler GD. Inpatient pediatric migraine treatment: does choice of abortive therapy affect length of stay? J Pediatr. 2016;179:211–5. This article clarifies that the use of opioids as part of an inpatient treatment plan for pediatric migraine actually leads to longer stays. CrossRefGoogle Scholar
  67. 67.
    • Leung S, Bulloch B, Young C, Yonker M, Hostetler M. Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department. Headache. 2013;53:491–197. Not new, but still one of the most clear descriptions of an emergency department protocol for migraine treatment in a children’s hospital. CrossRefGoogle Scholar
  68. 68.
    Kaar CR, Gerard JM, Nakanishi AK. The use of a pediatric migraine practice guideline in an emergency department setting. Pediatr Emerg Care. 2016;32(7):435–9.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Reena Gogia Rastogi
    • 1
  • Clarimar Borrero-Mejias
    • 1
  • Carolyn Hickman
    • 1
  • Kara Stuart Lewis
    • 1
  • Robert Little
    • 1
  1. 1.Barrow Neurological Institute at Phoenix Children’s HospitalPhoenixUSA

Personalised recommendations